ArticleBritish journal of cancer2008

Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.

T L Lash et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.